Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00920075 · ClinicalTrials.gov registry record
Alendronate in Juvenile Osteoporosis
A clinical trial, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- 11
- Enrollment target
NCT00920075 is a clinical trial that has completed, run by Medical University of South Carolina. The registered enrollment target is 11 participants.
The verdict
NCT00920075 has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- 11 participants
- Enrollment target
Study Summary
The investigators earlier have shown that treatment of patients with juvenile osteoporosis with alendronate (Fosamax) for 12 months increased the bone density without side effects. In an open label study (10 patients) and double blind, crossover study (11 patients alendronate and 11 patients placebo), the investigators have further observed that alendronate increased the bone density significantly where as placebo (calcium and vitamin D) increased only minimally. These trials were completed. Thus, a post study is designed to evaluate the current status of the bone density and fractures after the patients discontinued the alendronate treatment. No treatment is involved.
Interventions
- DRUG Alendronate (Fosamax)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2009-07 |
| Est. Completion | 2010-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00920075
The ClinicalTrials.gov registry entry for NCT00920075 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alendronate (Fosamax) is the first listed.
NCT00920075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00920075 about?
NCT00920075 is a clinical study titled "Alendronate in Juvenile Osteoporosis". The investigators earlier have shown that treatment of patients with juvenile osteoporosis with alendronate (Fosamax) for 12 months increased the bone density without side effects. In an open label study (10 patients) and double blind, crossover study (11 patients alendronate and 11 patients placebo...
What is the current status of trial NCT00920075?
This trial is currently completed. The enrollment target is 11 participants. The study started on 2009-07. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00920075?
The interventions under investigation include: Alendronate (Fosamax) (DRUG).
Who is sponsoring clinical trial NCT00920075?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.